Suspension or Delay of Joint Research Due to Changes in Pharmaceutical Company Policies
First written in FY2023. 3 of 7 entries say "Materialised", first in 2026-04-13. Latest entry: FY2026-H1.
Veritas In Silico moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
4 other companies' latest entry also says "Materialised".
- FY2026-H1MaterialisedAnnual report
「The joint research with Takeda Pharmaceutical Company Limited had produced certain results, but following discussions and consideration by both companies, it ended in April 2026.」
The risk of interruption or termination of joint research with a partner materialized in the conclusion of the joint research with Takeda Pharmaceutical Company Limited. However, the text states that this followed discussions and consideration by both companies and does not attribute it to a change in the partner’s policy. - FY2025RestatedAnnual report
「In addition to these general circumstances, our platform business involves uncertainties, including the fact that the progress of drug-discovery research cannot be controlled solely at our discretion and may be affected by the policies and decisions of our partners.」
The company continues to recognize the risk that the progress of joint research may be affected by partners’ policies and decisions. - 2026-03-02WorsenedGeneral Meetings of Shareholders
「Recently, major pharmaceutical companies worldwide have shown a tendency to scale back their in-house research and development, and the business environment surrounding us is changing rapidly. This is a significant headwind for our platform business, which conducts joint drug discovery research with pharmaceutical companies using our AI drug discovery platform, aibVIS.」
The trend of major pharmaceutical companies restraining research and development was explicitly described as a headwind for the platform business. - FY2023First statedAnnual report
「If an agreement is terminated or research is interrupted, discontinued or delayed due to factors beyond our control, such as changes in a partner’s business environment or management policy, our business strategy and business plans may change, potentially affecting our business, financial condition and operating results.」
The platform business depends on the business environment and policies of partners for the progress of research.